Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: A combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5529-5540

  Frank, M ^a,b   Von Kleist, Max ^b   Kunz, A ^c   Harms, G ^c   Schutte C ^b   Kloft, Charlotte ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; BODY WEIGHT; BREAST FEEDING; COST EFFECTIVENESS ANALYSIS; DELIVERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HIGH RISK INFANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NEWBORN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PLACENTAL TRANSFER; POINT MUTATION; PREGNANT WOMAN; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; STEADY STATE; STOCHASTIC MODEL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MODELS, BIOLOGICAL; NEVIRAPINE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 81555201927     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00741-11     Document Type: Article

References (62)

1. Alfonsi, A., E. Cances, G. Turinici, B. Ventura, and W. Huisinga. 2005. Exact simulation of hybrid stochastic and deterministic models for biochemical systems. ESAIM Proc. 14:1-23.
2. Arrive, E., et al. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36:1009-1021. (Pubitemid 350018545)
3. Bedri, A., et al. 2008. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 372:300-313.
4. Benaboud, S., et al. 2011. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob. Agents Chemother. 55:331-337.
5. Chaix, M. L., et al. 2006. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J. Infect. Dis. 193:482-487.
6. Chasela, C. S., et al. 2010. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N. Engl. J. Med. 362:2271-2281.
7. Chi, B. H., et al. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705. (Pubitemid 350100773)
8. Coffie, P. A., et al. 2008. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin. Infect. Dis. 46:611-621. (Pubitemid 351263504)
9. Cooper, C. L., and R. P. van Heeswijk. 2007. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 8:1-7. (Pubitemid 46117834)
10. Coovadia, H., et al. 2011. HPTN: efficacy of extended daily infant NVP through age 6 month compared to 6 weeks for postnatal PMTCT of HIV through breastfeeding, abstr. 123LB. Abstr. Conf. Retroviruses Opportun. Infect. http://www.retroconference.org/2011/Abstracts/42412.htm.
11. Cressey, T. R., et al. 2005. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 38:283-288. (Pubitemid 40333492)
12. De Cock, K. M., et al. 2000. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283:1175-1182. (Pubitemid 30126606)
13. de Maat, M. M., et al. 2002. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br. J. Clin. Pharmacol. 54:378-385.
14. de Vincenzi, I. 2011. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect. Dis. 11:171-180.
15. Dixit, N. M., and A. S. Perelson. 2004. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J. Theor. Biol. 226:95-109. (Pubitemid 37445213)
16. Elsherbiny, D., et al. 2009. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur. J. Clin. Pharmacol. 65:71-80.
17. Eshleman, S. H., et al. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957. (Pubitemid 32980636)
18. Grant, R. M., et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
19. Guay, L. A., et al. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802. (Pubitemid 29415583)
20. Havlir, D. V., S. Eastman, A. Gamst, and D. D. Richman. 1996. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:7894-7899. (Pubitemid 26339097)
21. Huang, Y., S. L. Rosenkranz, and H. Wu. 2003. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 184:165-186. (Pubitemid 36876936)
22. Jackson, J. B., et al. 2000. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14:F111-F115.
23. Jackson, J. B., et al. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868. (Pubitemid 37130095)
24. John-Stewart, G., et al. 2004. Breast-feeding and transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35:196-202. (Pubitemid 38133745)
25. Jourdain, G., et al. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240. (Pubitemid 38922817)
26. Kappelhoff, B. S., et al. 2005. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. 10:145-155. (Pubitemid 40767640)
27. Kumwenda, N. I., et al. 2008. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med. 359:119-129. (Pubitemid 351962035)
28. Kunz, A., et al. 2009. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J. Antimicrob. Chemother. 63:170-177.
29. Lockman, S., et al. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356:135-147. (Pubitemid 46089674)
30. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
31. Markowitz, M., et al. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77:5037-5038. (Pubitemid 36402857)
32. Martinez-Picado, J., and M. A. Martinez. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134:104-123.
33. McIntyre, J. A., et al. 2009. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 6:e1000172.
34. Miotti, P. G., et al. 1999. HIV transmission through breastfeeding: a study in Malawi. JAMA 282:744-749. (Pubitemid 29404380)
35. Mirochnick, M., et al. 1998. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J. Infect. Dis. 178:368-374. (Pubitemid 28347918)
36. Moorthy, A., et al. 2009. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 4:e4096.
37. Musoke, P., et al. 1999. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 13:479-486.
38. Omer, S. B. 2011. Twelve-month follow-up of six week extended dose nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 25:767-776.
39. Palumbo, P., et al. 2010. Antiretroviral treatment for children with peripartum nevirapine exposure. N. Engl. J. Med. 363:1510-1520.
40. Perelson, A. S. 2002. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2:28-36. (Pubitemid 37328773)
41. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. (Pubitemid 26097216)
42. Petra Study Team. 2002. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359:1178-1186.
43. Rosario, M. C., P. Jacqmin, P. Dorr, E. van der Ryst, and C. Hitchcock. 2005. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin. Pharmacol. Ther. 78:508-519. (Pubitemid 41698905)
44. Sampah, M. E. S., L. Shen, B. L. Jilek, and R. F. Siliciano. 2011. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:7613-7618.
45. Sedaghat, A. R., J. B. Dinoso, L. Shen, C. O. Wilke, and R. F. Siliciano. 2008. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. U. S. A. 105:4832-4837. (Pubitemid 351753832)
46. Shapiro, R. L., et al. 2010. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N. Engl. J. Med. 362:2282-2294.
47. Shen, L., et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766. (Pubitemid 351951518)
48. Stocker, H., et al. 2004. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:4148-4153. (Pubitemid 39434868)
49. Stringer, J. S., et al. 2003. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 17:1659-1665. (Pubitemid 36951686)
50. Taha, T. E., et al. 2003. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 362:1171-1177. (Pubitemid 37255341)
51. Tuckwell, H. C., and E. Le Corfec. 1998. A stochastic model for early HIV-1 population dynamics. J. Theor. Biol. 195:451-463. (Pubitemid 28558501)
52. Tuckwell, H. C., P. D. Shipman, and A. S. Perelson. 2008. The probability of HIV infection in a new host and its reduction with microbicides. Math Biosci. 214:81-86.
53. UNAIDS. 2010. UNAIDS report on the global AIDS epidemic. http://www.unaids.org/globalreport/Global-report.htm.
54. von Kleist, M., and W. Huisinga. 2009. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. Eur. J. Pharm. Sci. 36:532-543.
55. von Kleist, M., S. Menz, and W. Huisinga. 2010. Drug-class specific impact of antivirals on the reproductive capacity of HIV. PLoS Comput. Biol. 6:e1000720.
56. Wei, X., et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
57. WHO. 2010. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html.
58. WHO. 2006. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. http://www.who.int/hiv/pub/mtct/antiretroviral/en/index.html.
59. WHO. 2010. Guidelines on HIV and infant feeding. http://www.who.int/ child-adolescent-health/documents/9789241599535/en/index.html.
60. Wiktor, S. Z., et al. 1999. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 353:781-785. (Pubitemid 29110402)
61. Wilkinson, D. J. 2006. Stochastic modelling in systems biology. Chapman & Hall/CRC, Boca Raton, FL.
62. Zhou, Y., H. Zhang, J. D. Siliciano, and R. F. Siliciano. 2005. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J. Virol. 79:2199-2210. (Pubitemid 40204577)